INNOVIVA, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses (Deprecated 2013-01-31)
INNOVIVA, INC. (INVA) had Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses (Deprecated 2013-01-31) of $28.00 thousand as of 2012-12-31, per its 10-K filed 2013-02-26.
Discontinued › Notes › Investments
us-gaap:AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses2 · last filed 2013-02-26
- 2012-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses (Deprecated 2013-01-31) $28.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses (Deprecated 2013-01-31) |
|---|---|
| 2012-12-31 | $28.00K 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |